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DEFECTIVE CD2 PATHWAY T CELL ACTIVATION IN 
SYSTEMIC LUPUS ERYTHEMATOSUS 
DAVID A. FOX, JO ANN MILLARD, JONATHAN TREISMAN, WENDY ZELDES, ALICE BERGMAN, 
JOEL DEPPER, ROBERT DUNNE, and W. JOSEPH McCUNE 
CD2 (‘Ill; sheep erythrocyte receptor) is the 
surface component of an alternative, antigen-indepen- 
dent pathway of human T cell activation. The response 
to certain anti-CD2 antibodies is relatively independent 
of accessory cell signals and therefore provides a direct 
measurement of T cell function. The CD2 pathway may 
be important in the differentiation of thymocytes, on 
which the expression of CD2 precedes the appearance of 
the CD3-T cell receptor complex. In view of the im- 
paired T cell regulation of immune responses in patients 
with systemic lupus erythematosus (SLE), we examined 
the activation of peripheral blood lymphocytes by anti- 
CD2 antibodies in 57 SIX patients and 32 normal 
control subjects. The CD2 pathway response was lower 
in the SLE patients (P < 0.0001); 18 of the 57 SLE 
patients had a lower response than any of the control 
subjects. The SI,E low-responder patients did not differ 
from the normal-responder patients in terms of disease 
activity or use of antiinflammatory and immunosuppres- 
sive medications. Low responses to anti-CD2 were cor- 
rected to normal by the coaddition of a submitogenic 
amount of phorbol myristate acetate (1 ng/ml). In some 
From the Division of Rheumatology, Rackham Arthritis 
Research Unit, Department of Internal Medicine. and the Multipur- 
pose Arthritis Center, IJniversity of Michigan Medical Center, Ann 
Arbor. 
Supported by the 1,upus Foundation of America. Dr. Pox’s 
work is supported by an Arthritis Foundation Investigator Award 
(Michigan chapter), by NIH grant AR-38477, and by the Leyota M. 
Wilson fund of the University of Michigan Medical School. 
David A. Fox, MI); Jo Ann Millard, MSc; Jonathan lreis-  
man, MD; Wendy Zeldes, 13Sc; Alice Hergman, BSc; Joel Depper, 
MI); Robert 1)unne. HSc; W. Joseph MeCune, MD. 
Address reprint requests to David A. Fox, MD, Division of 
Rheumatology, R4570 Kresge Eye Institute, University of Michi- 
gan, Ann Arbor, MI 48109-0531. 
Submitted for publication April 24, 1990; accepted in re- 
vised form November 14, 19W. 
low-responder patients, the responses were normalized 
by the removal of non-T cells. The data indicate that 
some SLE patients have impaired responses to CD2 
pathway activation and that this may reflect intrinsic T 
cell defects and/or regulatory influences of non-T cells. 
The clinical manifestations of systemic lupus 
erythemdtosus (SLE) are produced, in large part, by 
the effects of pathogenic autoantibodies. Underlying 
the B lymphocyte abnormalities in SLE,  however, are 
disturbances in regulatory T cell function. T lym- 
phopenia is common (1-3), and the proportions of T 
cells in defined phenotypic/functionaI subsets are fre- 
quently deranged (2-6). T cell function in SLE patients 
is deficient in several ways, including proliferative 
responses (7-lo), production of and response to inter- 
leukin-2 (IL-2) ( 1  1-17), generation of suppressor cell 
function (18-22), and responses in the autologous 
mixed lymphocyte reaction (21,23). 
Anti-T cell autoantibodies probably play a ma- 
jor role in producing these abnormalities. Such anti- 
bodies are heterogeneous, and may be directed at 
structures on activated T cells or on subsets required 
for the generation of suppressor function (24-31). A 
correlation has been found between the major antilym- 
phocyte antibody specificity in the sera of individual 
patients and the concurrent abnormalities in the T cell 
subsets and functions (20,27,29,31). 
It is now realized that multiple T lymphocyte 
surface structures are involved in the activation of 
resting T cells. Prominent among these is the T cell 
antigen receptor complex (CD3-TCR). A distinct 
structure, which has been termed CD2 (previously 
known as T11 , and first identified as the T cell receptor 
for sheep erythrocytes [32]), can also convey activa- 
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tion signals both to mature T cells and to thymocytes 
(33,34). Although activation through CD2 was first 
demonstrated using combinations of anti-CD2 antibod- 
ies, similar effects have been found using a natural 
ligand of CD2, termed lymphocyte function- 
associated antigen 3 (LFA-3; recently designated 
CD58) (35,36). LFA-3 is an integral membrane com- 
ponent of cells with which T lymphocytes interact, 
such as thymic epithelial cells and monocytes (37). 
In the course of recent studies of intravenous 
pulse cyclophosphamide treatment of severe SLE, it 
was observed that the in vitro proliferative response to 
anti-CD2 antibodies diminished during treatment and 
at followup, without a concurrent reduction in other T 
cell responses (38). It was also apparent that the 
pretreatment response of the patients' T cells to anti- 
CD2 antibodies was frequently very low. Since abnor- 
malities of CD2-mediated T cell activation have not 
previously been documented in SLE, the present 
study was undertaken to investigate the integrity of 
this activation pathway in a large group of SLE 
patients with various levels of disease activity and 
severity. The results, when compared with those from 
the healthy control subjects, indicate that approxi- 
mately 30% of SLE patients have very low prolifera- 
tive responses to anti-CD2 antibodies. This low re- 
sponse cannot be explained by the level of disease 
activity or by the effects of medications. 
PATIENTS AND METHODS 
Patients and controls. Peripheral blood mononuclear 
cells were obtained from 57 patients with SLE (8 men and 49 
women) who were receiving followup care at the University 
of Michigan Medical Center. These patients met the Amer- 
ican Rheumatism Association 1982 revised criteria for the 
classification of SLE (39), and they had not been treated with 
cyclophosphamide. The mean * SD age of the patients was 
34 * 11 (range 19-62). Characteristics of these patients, who 
represented a wide range of disease manifestations and 
levels of activity, are described below (see Results). 
The control group consisted of 32 healthy volunteers 
(14 men and 18 women), with a mean f SD age of 30 * 7 
(range 19-55). In certain experiments, additional mononu- 
clear cell samples were obtained from SLE patients who had 
been treated with intravenous cyclophosphamide within the 
previous 3 months. 
Activation of T cells. Mononuclear cells were isolated 
from heparinized peripheral blood by centrifugation over 
Ficoll-Hypaque (Pharmacia, Piscataway, NJ), followed by 3 
washes in minimum essential medium containing 2% calf 
serum. For some experiments, T cells (E+) and non-T cells 
(E-) were separated by rosetting with sheep erythrocytes. 
Aliquots of 100,000 cells were cultured in RPMI 1640 me- 
dium with 10% fetal calf serum in 96-well round-bottom 
plates in a volume of 0.2 ml/well. Triplicate wells contained 
either no stimulus or phytohemagglutinin (PHA) (0.5 pg/ml; 
Burroughs Wellcome, Research Triangle Park, NC), phorbol 
myristate acetate (PMA) (1 ng/ml; Sigma, St. Louis, MO), a 
mitogenic combination of 2 anti-CD2 monoclonal antibodies 
(anti-Tll, and anti-Tll, [see ref. 33]), a mitogenic anti-CD3 
antibody (anti-T3B [see ref. 40]), or tetanus toxoid (final 
concentrations 1:200 and 1:400; Massachusetts Department 
of Public Health, Boston, MA), or combinations of some of 
these stimuli. The monoclonal antibodies were generously 
provided by Drs. Stuart Schlossman and Ellis Reinherz 
(Dana-Farber Cancer Institute, Boston, MA), and were used 
at final concentrations of 1500. 
Cultures were maintained at 37°C in a humidified 
incubator with 5% CO,. To detect cell proliferation, 0.8 WCi 
of tritiated thymidine was added on day 4 (day 6 for tetanus 
toxoid) and cultured for 18 hours. Cultures were then 
harvested using a multichannel instrument and counted in a 
liquid scintillation counter. Background counts per minute 
from unstimulated cultures were subtracted from the raw 
counts. For tetanus toxoid, the cpm from the dilution that 
yielded the higher proliferative response for an individual 
subject was selected. 
Surface marker analysis. A panel of monoclonal 
antibodies was used to quantitate surface marker expression 
on mononuclear cells from patients with SLE and from 
control subjects. Markers assessed included pan-T cell 
antigens (CD2 and CD3), T cell subset markers (CD4, CD8, 
and CDw60), T cell activation antigens (CD25 and CD26), 
HLA-DR, CD20 (a mature B cell antigen), CD56 (a natural 
killer cell antigen), and CDl lb  (expressed on monocytes and 
a small T cell subset). Antibodies identifying T cell antigens 
(33,34,4143), except for anti-CDw60 (44), were the gener- 
ous gift of Drs. Stuart Schlossman and Ellis Reinherz. Other 
antibodies were generously provided by Drs. Lee Nadler 
(Dana-Farber Cancer Institute) (45,46), Jerome Ritz (Dana- 
Farber Cancer Institute) (47), and Robert F. Todd (Univer- 
sity of Michigan) (48). 
For surface marker analysis, aliquots of one million 
cells were incubated with optimal concentrations of monoclo- 
nal antibodies in a total volume of 0.2 ml for 30 minutes at 
4°C. Following 2 washes, a saturating amount of fluorescein- 
conjugated goat anti-mouse immunoglobulin (Tago, 
Burlingame, CA) was added. After 30 minutes at 4"C, the 
samples were again washed twice, fixed with 1 ml of 1% 
formalin, and analyzed with an Epics C flow cytometer 
(Coulter, Hialeah, FL). 
Measurement of interleukin-2 receptors (IL-2R). 
Mononuclear cells from patients with either high or low 
proliferative responses to antLCD2 monoclonal antibodies 
(anti-T11, + anti-T1 13) were cultured with these antibodies 
(1 500) for 72-96 hours in RPMI 1640 medium with 10% fetal 
calf serum at two million cells per ml. Cultured cells were 
washed 5 times, and resuspended at a concentration of ten 
million viable cells per ml in binding medium containing 
RPMI 1640 with 1% bovine serum albumin, 1 mg/ml of 
human IgG, 25 mM HEPES, and 0.1% sodium azide. For 
measurement of total IL-2R, triplicate aliquots of one million 
cells were incubated with 19 ng of tritiated anti-IL-2R 
(anti-Tac) monoclonal antibody for 60 minutes at room 
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temperature in a total volume of 0.2 ml. The mixture was 
then layered over a 0.75 ml sucrose cushion, centrifuged, 
and the cell pellet was recovered for liquid scintillation 
counting. Measurement of high-affinity receptors was done 
using similar procedures, but in the presence of 10-20 fM 
IL-2 labeled with lZ5I (Amersham, Arlington Heights, IL) 
and 20 pM unlabeled IL-2 (Cetus, Emeryville, CA). 
Measurement of IL-2 production. Supernatants of 
cells cultured for 48 hours with various activation stimuli 
were stored at -8o”C, then added at dilutions of 1:2 to 1:16 
to triplicate wells containing 5,000 CTLL-2 cells. Prolifera- 
tion of the CTLL-2 indicator cells was quantitated by 
measuring thymidine incorporation following addition of 0.8 
pCi of tritiated thymidine per well for the final 6 hours of a 
24-hour culture. 
Induction of the T11, epitope. Incubation of T cells 
with anti-T11, for 30 minutes at 4°C induces expression of 
the T11, epitope (33). To determine if this occurred in T cells 
from SLE patients, E +  cells were incubated with anti-Tll, 
(IgG2) as described (33), then stained with anti-T1 I,  (IgG3) 
and fluoresceinated y3-specific anti-mouse IgG (The Binding 
Site, Birmingham, UK) or with control antibodies. Samples 
were then analyzed by flow cytometry. 
Calcium fluxes. T cells from SLE patients were 
suspended at a concentration of 20 x lo6 cells/ml in culture 
medium (RPMI 1640 supplemented with 10% fetal calf 
serum, 1% glutamine, and 1% penicillin/streptomycin). Cells 
were loaded with the dye indo-1 (Molecular Probes, Eugene, 
OR), at a concentration of 1.5 p M ,  and maintained at 37°C 
for 25 minutes in the dark (49). Cells were washed 3 times 
and resuspended in culture medium. Aliquots of lo6 cells 
were kept on ice until they were placed in the flow cyto- 
meter. The ratio of vio1et:blue fluorescence was determined 
as a function of cell number; the change in the mean ratio 
was used as a measure of the extent of flux. Readings were 
taken at multiple time points after the addition of anti-CD2 
antibodies (1:500) or ionomycin (5 pg/ml). 
Statistical analysis. Responses of SLE and control T 
cells were compared using Student’s t-test. Correlations 
within groups of SLE patients were determined by linear 
regression. Differences in CD2 responses between subsets of 
SLE patients were analyzed using the Wilcoxon rank sum test. 
RESULTS 
T cell proliferative responses to a panel of 
mitogenic stimuli were measured using mononuclear 
cells from 57 patients with SLE and 32 control subjects 
(Figure 1). The mean response to anti-CD2 antibodies 
in the SLE group was less than 60% of that in the 
control group, and this difference was highly signifi- 
cant ( P  < 0.0001). This result could not be explained 
by the higher proportion of males in the control group: 
The response of the male controls to CD2 activation 
was 63,128 * 9,931 cpm (mean * SEM), which is not 
significantly different from that of the female controls 
(69,283 t 7,573 cpm). Differences in proliferative 
responses between the SLE and control groups were 
Anti-CD2 PHA Anll-CD3 PMA Anti-CD3 Tetanus 
+ PMA toxoid 
Figure 1. Proliferative responses of mononuclear cells from pa- 
tients with systemic lupus erythematosus (SLE) and from healthy 
controls to various T cell stimuli. Proliferation was measured on day 
4 of culture, except for tetanus toxoid, which was measured on day 
6. PHA = phytohemagglutinin; PMA = phorbol myristate acetate. 
also seen with other stimuli, such as PHA, tetanus 
toxoid, and anti-CD3 plus PMA, but at a level of 
significance that was not as great as that seen with the 
CD2 responses (Figure 1). Anti-CD3 or PMA used 
separately induced comparable levels of proliferation 
in the SLE and control groups. 
All of the normal subjects had anti-CD2 anti- 
body responses that were over 20,000 cpm, but 18 of 
the 57 SLE patients had responses that were lower 
than 20,000 cpm. This latter group was designated 
“low-responder,’’ and the remaining SLE patients 
were designated “normal-responder.” Almost all of 
the differences in the CD2 responses between the SLE 
patients and the control group were the result of the 
low-responder patients, many of whom showed counts 
that were only barely detectable over background in 
the presence of anti-CD2 antibodies. These low re- 
sponses were noted at multiple durations of culture 
(day 2 to day 6), in the presence of higher concentra- 
tions of antLCD2 antibodies (1: loo), and when cells 
were precultured in medium alone for 24-48 hours 
prior to stimulation (data not shown). 
Data from the proliferation studies and from 
concurrent flow cytometric surface marker quantita- 
tion were then analyzed to determine whether other 
immunologic parameters correlated with the magni- 
tude of the CD2 response, either in normal subjects or 
in SLE patients. As shown in Table 1 ,  many of these 
parameters were significantly different between the 
SLE and control groups. The SLE group exhibited a 
marked T lymphopenia, which is consistent with find- 
ings from previous studies (1-3). The proportion of 
natural killer cells (CD56-t) among the mononuclear 
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Table 1. Correlation of immunologic parameters with CD2 activation responses in patients with 
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38,967 f 4,099 
48,077 f 3,340 
7,932 * 1,320 
14,686 f 3,100 
81,076 f 6,205 
10,714 t 2,501 
37 f 3 
21 f 2 
13 f 1 
31 t 3 
2.1 f 0.2 
11 * 1 
9 f 1  
6 f l  
4 f 0.5 
11 t I 
2 f 0.3 
6 5 1  
0.38 f 0.04 
0.07 f 0.01 
0.19 f 0.03 
66,590 * 6,004 
65,467 5 4,531 
10,360 f 5,322 
17,801 * 4,547 
114,827 t 7,797 
23,116 f 2,435 
63 f 3 
38 f 3 
16 t 2 
63 f 4 
2.9 * 0.3 
7 f 1  
18 f 2 
3 * 0.4 
10 f 1 
17 & 2 
2 f 0.4 
8 f 1  
0.24 t 0.02 
0.03 f 0.001 
































































* Values are the mean f SEM cpm (proliferative response) or the mean f SEM percentage of 
mononuclear cells positive over background fluorescence, as determined by flow cytometric analysis 
(surface markers). Terms in parentheses are other names that have been used to identify the cell 
surface markers listed. PHA = phytohemagglutinin; NS = not significant. PMA = phorbol myristate 
acetate; IL-2R = interleukin-2 receptor. 
cell population was also reduced, but the proportion of 
B lymphocytes and the proportion of Ia+ cells were 
increased. The calculated percentage of T cells bearing 
markers of activation (CD25 and CD26) was margin- 
ally greater in the SLE group. Although the percentage 
of CDw60+ mononuclear cells was lower among the 
SLE patient group, the calculated proportion of T cells 
that were CDw60+ was higher. (CDw60 is a marker of 
a T cell subset that accumulates in autoimmune lesions 
[44,501). 
The reduced expression of CD2 was especially 
notable in the SLE group, and the proportion of CD2-t 
cells was somewhat lower than the proportion of 
CD3+ cells. This was, in part, due to the reduced 
intensity of CD2 expression that was seen in cells from 
many of the SLE subjects, causing some cells within 
the CD2 peak to fall just below the cutoff for back- 
ground fluorescence (data not shown). The data, there- 
fore, do not necessarily indicate the existence of a 
large CD3+, CD2- T cell subset in the SLE patients. 
Furthermore, low-intensity expression of CD2 in SLE 
patients’ cells did not appear to explain the low 
proliferative responses to anti-CD2 antibodies, since 
within the SLE group, no correlation was found be- 
tween the proportion of cells bearing CD2 (or any 
other surface marker) and the CD2 activation response 
(Table 1). In the control group, but not the SLE group, 
the percentage of mononuclear cells and the calculated 
proportion of T cells bearing markers of T cell activa- 
tion (CD25 and CD26) correlated positively with the 
CD2 response (Table 1). There was correlation of CD2 
responses with other proliferative responses, although 
the relationships within the SLE group were different 
from those within the control group. 
To determine whether the low CD2 pathway 
responses in SLE patients reflected the presence of 
excessive numbers of monocytes in culture or the 
inhibitory effects of monocytes and other non-T cells, 
proliferation was measured using isolated T cells that 
had been obtained by rosetting with sheep erythro- 
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Table 2. Proliferative responses of mononuclear cell subsets from patients with systemic lupus erythematosus (SLE) and from a normal 
control subject to anti-CD2 and anti-CD3 antibodies* 
Anti-TI I, + anti-TI I, Anti-CD3 
5 x 104 E+,  5 x 104 E+,  5 x 104 E+, 5 x 104 E+,  
IOSPBMC 5 x 104 E+ 2.5 x 104 E- 5 x 104 E- 105 PBMC 5 x lo4 E+ 2.5 x I O ~ E -  5 x 104 E- 
Normal subject 38,723 30,983 ND 26,066 7,759 ND ND ND 
SLE patient 
Patient I 837 3,791 ND 0 1,447 ND ND ND 
Patient 2 0 7,409 6,041 0 17,258 5,142 19,699 11,677 
Patient 3 0 44,902 37,332 2,722 10,086 6,509 ND ND 
Patient 4 462 64,870 5 1,565 16,100 3,705 40 21,509 24,692 
Patient 5 56,903 45,293 54,545 47,184 47,775 509 18,257 17,921 
* Values are the mean cpm in triplicate cultures, as measured on day 4. Data are representative of the 12 subjects studied (2 normal controls 
and 10 SLE patients). E+ and E- cells were separated by rosetting with sheep erythrocytes. PBMC = peripheral blood mononuclear cells; 
ND = not done. 
cytes. As shown in Table 2, removal of non-T cells 
from the mononuclear cell population restored to 
normal the low responses in some, but not all, SLE 
patients’ cells. Therefore, the deficiencies in CD2 
pathway function in low-responder SLE patients may 
be due to intrinsic T cell abnormalities, as well as the 
negative effects of non-T cells. Responses to anti-CD3 
were lower in the absence of E- cells, since mono- 
cytes are important for the T cell response to soluble 
anti-CD3 (51). 
Experiments were then performed to determine 
whether the anti-CD2 response in low-responder SLE 
subjects could be restored to normal by the addition of 
a second activation stimulus. In these experiments, 2 
types of SLE low responders were studied, including 
some of the subjects described above, as well as a 
group of SLE patients whose CD2 responses became 
low after treatment with intravenous cyclophospha- 
mide (38). The results did not differ between these 
groups of low responders, and the findings are there- 
fore combined as a single group for discussion here. 
The findings for 20 SLE low responders were 
compared with those of 12 SLE normal responders in 
terms of their response to anti-CD2 antibodies or 
PMA, or both. For cells from the SLE normal re- 
sponders, the combination of anti-CD2 and PMA gave 
an additive, rather than a synergistic, response (Table 
3). Despite also having a somewhat lower response to 
PMA, cells from the SLE low responders had a 
synergistic response to anti-CD2 antibodies plus PMA, 
yielding cpm that were not significantly different from 
the cpm in the normal-responder group. Of the 20 low 
responders to anti-CD2, 17 had cpm >20,000 when 
PMA was included in the culture. Some reconstitution 
of the CD2 response was also seen when IL-2 (1-16 
unitdml), instead of PMA, was added to the medium, 
although this was generally less effective (data not 
shown) . 
Taken together, the above data suggest that T 
cells from a subgroup of patients with SLE are not 
effectively activated by the triggering of CD2, although 
full activation can be restored by inclusion of a comi- 
togenic stimulus. Defective responses could poten- 
tially reflect inadequate initial transmembrane signal- 
ing, which could, in turn, be due to insufficient 
induction of the TII, epitope. To determine whether 
the anti-T11, antibody induced prompt expression of 
the T11, epitope, SLE patient T cells were incubated 
with anti-T1 l,, and then stained with anti-TI I ,  and 
fluorescein isothiocyanate-conjugated anti-mouse Ig 
that bound to the anti-Tll,, but not the anti-Tll,, 
antibody. Prompt expression of T11, (50-100% of T 
Table 3. 
antibodies* 
Response of cells from patients with systemic lupus erythematosus (SLE) to anti-CD2 
Anti-CD2 PMA Anti-CD2 + PMA 
Normal responders (n = 12) 54,719 t 5,805 22,997 t 4,162 80,360 -t 10,454 
Low responders (n = 20) 5,508 f 1,251 9,555 ? 1,828 62,740 ? 8,730 
P (normal vs. low) <0.0001 <0.05 >0.05 
* See Patients and Methods for definitions of responder status. Values are the mean 2 SEM cpm. 
PMA = phorbol myristate acetate. 
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Figure 2. Generation of calcium fluxes in T cells from patients with 
systemic lupus erythematosus (SLE) by antLCD2 antibodies. Cells 
were loaded with indo-1 and analyzed by flow cytometry. AntLCD2 
antibodies or ionomycin (iono) were added at  time 0. Values are the 
change in the mean fluorescence intensity (AMFI) of the vio1et:blue 
ratio over time. Experiment 1 = cells from a low responder to 
anti-CD2 antibodies; experiments 2 and 3 = cells from 2 different 
normal responders (see Patients and Methods for details). Data are 
representative of 12 experiments (8 with SLE patients and 4 with 
control subjects). 
cells positive within 30 minutes) occurred in all 6 
experiments, regardless of the level of the proliferative 
response to anti-T11, plus anti-Tll, (data not shown). 
The T11, and Tl l ,  epitopes were able to generate a 
transmembrane activation signal in all cases, as dem- 
onstrated by significant calcium fluxes in T cells from 
both high- and low-responder SLE patients (Figure 2). 
Similar fluxes were observed with cells from control 
subjects (data not shown). 
One of the components of T cell activation is 
induced expression of high-affinity IL-2 receptors that 
contain 2 distinct subunits (52). Experiments were 
therefore performed to measure both total and high- 
affinity IL-2R expression after anti-CD2 activation of 
T cells from both low- and normal-responder SLE 
subjects and from normal controls. As shown in Table 
4, the SLE low responders tended to have lower 
expression of high-affinity and total IL-2R than did the 
other groups, but these differences did not, in general, 
achieve statistical significance. Considerable heteroge- 
neity was present within each group. When total or 
high-affinity IL-2R expression was plotted against the 
response to anti-CD2 antibodies for all SLE patients 
whose data are included in Table 4, a significant 
correlation was not detected (data not shown). 
Table 4. Interleukin-2 receptor (IL-2R) expression following CD2 
activation in cells from patients with systemic lupus erythematosus 
(SLE) and from normal control subjects* 
High-affinity Total 
IL-2R IL-2R 
SLE low responders 498 f 103 3,701 ? 1,377 
SLE normal responders 818 f 421 9,946 t 3,752 
Normal controls (n = 3) 10,026 2 1,573 
P (SLE low responders NS NS 
(n = 6) 
(n = 4) 
1,388 -+ 842 
vs. SLE normal 
responders) 
vs. normal controls) 
P (SLE low responders NS <0.05 
~ 
* See Patients and Methods for definitions of responder status. 
Values are expressed as the mean 2 SEM no. of IL-2R. NS = not 
significant (P > 0.05). 
To measure the production of IL-2, superna- 
tants were collected from cultured SLE mononuclear 
cells that had been activated with a variety of stimuli. 
Representative findings are shown in Table 5 .  Only 
low levels of CTLL-2 proliferation occurred in the 
presence of supernatants from cultures activated with 
Table 5. 
from patients with systemic lupus erythematosus (SLE)* 
Interleukin-2 production following CD2 activation in cells 
PBMC CTLL-2 
Experiment 1 
AntLCD2 4,262 38 
PMA 185 0 
Anti-CD2 + PMA 42,825 540 
Anti-CD3 + PMA 37,747 70 1 
Anti-CD2 29,493 267 
PMA 11,887 138 
AntLCD2 + PMA 38,173 3,565 
Anti-CD3 + PMA 30,667 3,200 
Anti-CD2 5,047 162 
PMA 1,004 0 
Anti-CD2 + PMA 34,361 8,956 
Anti-CD3 + PMA 34,125 4,354 
Anti-CD2 15,665 90 
PMA 11,129 0 
Anti-CD2 + PMA 153,954 2,024 
Anti-CD3 + PMA 101,193 1,185 
* Values are the mean cpm in triplicate cultures and are repre- 
sentative of 16 experiments (10 low-responder SLE patients and 6 
normal-responder SLE patients; see Patients and Methods for 
details and definitions of responder status). Experiments 1 and 2 
used cells from SLE patients who had received intravenous cyclo- 
phosphamide within the preceding 3 months; experiments 3 and 4 
used cells from SLE patients who had received no cytotoxic drugs 
during the preceding year. PBMC = peripheral blood mononuclear 
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anti-CD2 antibodies, even when the anti-CD2 re- 
sponse was in the normal range (e.g., experiment 2 in 
Table 5) .  For the 6 experiments using supernatants 
from normal-responder SLE subjects, mean 2 SEM 
CTLL-2 proliferation was only 137 ? 56 cpm, which 
was not different from that found for the low- 
responder subjects. Similar low levels of CTLL-2 
proliferation were seen using supernatants from PMA- 
stimulated cultures. Supernatants of cells cultured 
Table 6. CD2 responses in clinical subsets of patients with sys- 
temic lupus erythematosus 
Feature present Feature absent 
at study, mean at study, mean 
Clinical characteristic cpm CPm P 
Disease activity 2 or 3 40,151 (28) 35,118 (20) 0.91 
Renal disease 39,502 (30) 37,549 (17) 0.96 
CNS disease 29,097 (17) 42,966 (31) 0.1 I 
ESR >50 mm/hour 40,972 (22) 31,327 (22) 0.19 
(0-3 scale) 
24,521 (15) 45,487 (32) 0.03 
37,942 (10) 38,906 (36) 0.96 
with anti-CD2 plus PMA generally supported much 
higher levels of CTLL-2 proliferation than did super- Low complement 35,294 (23) 39,168 (20) 0.75 
natants of cells cultured with either stimulus alone. 
Comparing anti-CD2 plus PMA supernatants with anti- NSAIDs 44,211 (14) 35,969 (31) 0.41 
Antimalarials 53,104 (7) 36,707 (38) 0.18 
CD2 supernatants, the degree of augmentation was Azathioprine 40,470 (7) 38,211 (39) 0.83 
>IO-fold in 11 of 16 experiments (including all in Table * The presence or absence of clinical variables at the time of study 5) ,  and >3-fo1d in (+ I month) was determined retrospectively by chart review. Not all 
difference was found between low-responder and information was available for all oatients. and the number reme- 
gg2!a 
Currently taking 
Of l6 experiments* no 
normal-responder SLE groups. 
The data described above and in Table 5 were 
obtained using a 1:4 dilution of supernatant in the 
CTLL-2 cultures, but similar patterns were seen with 
dilutions ranging from 1:2 to 1:16. The data described 
are for supernatants collected from cultures that did 
not contain anti-IL-2R antibody: In all experiments, a 
blocking anti-IL-2R antibody was included in parallel 
initial cultures to prevent utilization of newly pro- 
duced IL-2 (anti-TAC, at 1: loo), and the results were 
virtually the same as those obtained in the absence of 
this antibody (data not shown). The results do not, 
therefore, demonstrate distinct patterns of IL-2 secre- 
tion in SLE low versus SLE normal responders fol- 
lowing CD2 pathway activation. 
Clinical parameters were then analyzed in the 
SLE patients to determine whether low CD2 re- 
sponses correlated with the use of specific types of 
medications, the dosage of corticosteroids, or the 
clinical status. There was no significant positive or 
negative correlation between the magnitude of the 
response to anti-CD2 antibodies and the titer of anti- 
DNA antibodies, the serum creatinine level, the age of 
the patients, or the dosage of prednisone. The range of 
dosages of prednisone taken by the low-responder 
group was 0-60 mg/day, the same as that in the 
normal-responder group (except for 1 patient in the 
normal-responder group who was taking 120 mg/day). 
The CD2 responses of the SLE patients were 
then analyzed according to the presence or absence of 
the following clinical characteristics: high clinical ac- 
tivity score, renal disease, central nervous system 
disease, high erythrocyte sedimentation rate, serositis, 
cytopenia, hypocomplementemia (CH50, C3, or C4), 
sented is shown in parentheses. kNS = central nervous systkm; 
ESR = erythrocyte sedimentation rate; NSAIDs = nonsteroidal 
antiinflammatory drugs. 
and current use of a nonsteroidal antiinflammatory 
drug, antimalarial agent, or azathioprine. Responses to 
anti-CD2 antibodies did not differ between the groups 
with or without these individual characteristics, ex- 
cept for serositis, which was associated with a mod- 
estly lower CD2 response (Table 6). The data indicate 
that low CD2 responses in a subset of SLE patients are 
not accounted for by overall disease activity or by use 
of specific medications. 
DISCUSSION 
In this study, the integrity of CD2-mediated T 
cell activation was investigated in the peripheral blood 
cells of 57 SLE patients and 32 healthy control sub- 
jects. Significantly lower proliferative responses to a 
mitogenic pair of antLCD2 antibodies were noted in 
the SLE patients. The difference between the SLE and 
control groups could be accounted for by a low- 
responder subset of SLE patients, which composed 
-30% of the SLE group. Other T cell responses were 
also reduced in the SLE group, but the difference was 
especially prominent for the CD2 response. 
Most forms of T cell activation, including stim- 
ulation with mitogenic lectins or soluble antigen, re- 
quire substantial accessory cell help, which is usually 
provided by monocytes. Intact T cell responses there- 
fore depend upon normal function of both monocytes 
and T cells. Responses to soluble anti-CD3 also re- 
quire monocytes, in part to bind the Fc portion of the 
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anti-CD3 antibodies to Fc receptors on the monocyte 
surface (52), a requirement that can be bypassed by 
the addition of PMA (53). The anti-CD2 antibodies 
used in these studies activate normal T cells with little 
or no need for monocytes (33) and are therefore of 
special value as a direct probe of T cell function. This 
may be particularly useful in SLE, a disease in which 
monocyte function may be abnormal (54). 
Multiple abnormalities of surface antigen 
expression were noted on SLE mononuclear cells, 
including T lymphopenia and reduced CD2 expres- 
sion. None of these parameters correlated, however, 
with the level of CD2 responses, which indicates that 
defective responses did not exclusively reflect low 
CD2 expression. In the control group, the level of the 
CD2 response correlated with the proportion of T cells 
bearing markers of activation. In contrast, in the SLE 
group, despite higher proportions of activated cells, no 
such correlation was seen. This suggests that CD2 
responses may be regulated differently in SLE pa- 
tients, even in those who are normal responders, than 
in healthy control subjects. Validation of this hypoth- 
esis will, however, require better understanding of the 
CD2 activation pathway. 
Defective CD2 responses in low-responder 
SLE patients could be normalized by costimulation 
with minimally mitogenic doses of the phorbol ester 
PMA. In this respect, SLE low-responder T cells 
resembled normal thymocytes, which require 2 signals 
to proliferate through the CD2 pathway (3435). In the 
case of thymocytes, anti-CD2 antibodies induced 
IL-2R expression, but not IL-2 production-proliferation 
occurred only if IL-2 was exogenously provided (34) 
or if its synthesis was induced by PMA (55). In the 
case of SLE low responders, experiments designed to 
precisely localize the CD2 activation defect to either 
inadequate transmembrane signaling, IL-2R expres- 
sion, or IL-2 production did not yield a clear-cut 
answer. Expression of the T11, epitope and induction 
of calcium fluxes were normal in SLE low responders. 
Cells from SLE low responders tended to show lower 
high-affinity and total IL-2R induction by anti-CD2, 
but the differences between this group and the SLE 
normal responders or the healthy controls generally 
did not reach statistical significance. 
Interpretation of IL-2R expression in these ex- 
periments is complicated by the dependence of the full 
expression of IL-2R on the secretion of IL-2 (56). 
Detectable production of IL-2 following CD2 stimula- 
tion was low in both SLE low responders and SLE 
normal responders, unless PMA was added. It is 
possible that SLE normal responders produce low, but 
functionally important, amounts of IL-2 that are not 
detectable by currently available assays, and that 
inadequate IL-2 production limits proliferation in 
some of the SLE low responders. Alternatively, SLE 
normal responders might produce non-IL-2 T cell 
autocrine growth factors following CD2 activation, to 
a greater extent than the SLE low responders. The low 
IL-2 production found in this study closely parallels 
findings with PHA stimulation of T cells from patients 
with either active or inactive SLE (57). 
Patients with active SLE are deficient in the 
CD4+, CD45R+ suppressor inducer T cell subset (20), 
which has been reported to respond particularly well 
to CD2 stimulation (58). Although this subset was not 
measured in the present study, it is unlikely that 
deficiency of these cells would account for the SLE 
low-responder group, since (a) CD2 responses did not 
correlate with disease activity, and (b) T cell subsets 
other than the CD4+, CD45R+ population normally 
also respond vigorously to CD2 activation, as indi- 
cated by efficient triggering of helper function for immu- 
noglobulin production by anti-CD2 antibodies (59). 
One potential explanation for low CD2 re- 
sponses might be the presence of a (non-T) cell subset 
within the mononuclear cell population that sup- 
presses the CD2 response in the low-responder indi- 
viduals. In some but not all low responders, purifica- 
tion of T cells prior to culture significantly enhanced 
the CD2 response (Table 2). Taken together, the data 
suggest that the defective responses to anti-CD2 anti- 
bodies in the SLE low-responder individuals may 
represent an intrinsic T cell defect (or heterogeneous 
group of defects), the regulatory effects of non-T cells, 
and possibly, abnormal T cell responses to such reg- 
ulatory signals. Low responses do not appear to be the 
result of SLE-induced organ failure or administration 
of corticosteroids. Because initial signaling events (as 
judged by calcium fluxes in the presence of anti-CD2 
antibodies) appear to be intact, any intrinsic T cell 
defects may lie at later stages of the T cell activation 
process. Whether such defects relate in any way to the 
pathogenesis of SLE will require further investigation. 
It is certainly possible that similar abnormalities could 
be present in other autoimmune diseases, and that 
such abnormalities could be a secondary consequence 
of autoimmune processes. 
A role for the CD2 pathway has been postulated 
in the selection of T cells in the human thymus, since 
in vitro triggering of the thymocyte antigen receptor 
complex could be shown to provide a negative signal 
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under conditions in which CD2 triggering provided a 
positive signal (55,60). Based on these findings, it was 
hypothesized that thymocytes not subject to negative 
selection (cells lacking high-affinity autoreactivity) 
could expand and differentiate by activation through 
CD2 (60), particularly since a functional ligand of CD2 
has been shown to be present in the thymus (36,37). If 
responses to CD2 in low-responder individuals were 
defective throughout T cell ontogeny , including the 
thymocyte stage, a potential consequence could be 
alterations of the thymic selection process that might 
predispose to the later development of autoimmune 
disease. No data that directly support this hypothesis 
are currently available, however. 
It is intriguing that in SLE normal-responder 
subjects, intravenous cyclophosphamide treatment 
frequently leads to conversion to a CD2 low-responder 
state, despite preservation of other T cell proliferative 
responses (38). This indicates that even in SLE normal 
responders, the CD2 pathway is uniquely vulnerable 
and can be regulated in ways distinct from those of 
other T cell responses. (No information, however, is 
available regarding the effects of cyclophosphamide on 
CD2 responses in individuals without autoimmune 
disease.) Both constitutive and cyclophosphamide- 
induced CD2 low responsiveness were normalized by 
small concentrations of the comitogen PMA. This 
raises the possibility that signal transduction events 
normally culminating in the activation of protein ki- 
nase C were defective in these low responders, and 
that PMA bypassed the defective signaling step(s). 
Alternatively, the augmenting effect of PMA could 
reflect modulation of the expression of various T cell 
surface structures and/or effects on the expression of 
genes essential to T cell activation by mechanisms 
other than activation of protein kinase C. Additional 
work will be necessary to resolve these issues and to 
precisely identify the mechanisms of abnormal activa- 
tion through CD2 in patients with SLE. 
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